05 Nov OnKure Therapeutics, Inc.
/ PORTFOLIO Boulder, CO(NASDAQ: OKU)OnKure Therapeutics is a publicly listed company based in the US. OnKure is focused on the development of PI3Ka mutant subtype inhibitors. PI3Ka is a key oncogenic driver in a variety of cancers. The company's lead product, OKI-219, is in a Phase...